Selumetinib (AZD6244)

Status: Currently a NF2 Clinical Trial

Trade Name:

N/A

Synonyms:

AZD 6244, 606143-52-6, AZD6244, AZD-6244,
ARRY-142886, CHEMBL1614701, NCGC00189073-01,
PubChem21092, Selumetinib (USAN/INN)

Pharmaceutical Company:

AstraZeneca

Protein Target:

MAPK/ERK Pathway

Legal Status:

℞ - Prescription/Under Clinical Trial

Administered By:

Pill^[3]

Formula:

C₁₇H₁₅BrC_lFN₄O₃

ChemSpider:

8303141 (Accessed: 2018)

PubChem:

CID 10127622

Selumetinib (AZD6244) is a drug being investigated for the treatment of various types of cancer, for example non-small cell lung cancer (NSCLC). ^[4}

Treatment Information

UK Treatments: The role of insulin-like growth factors signaling in merlin-deficient human schwannomas

NF2 Trial:

Also Treatment For^[2]

1. Solid Tumors
2. Neurofibromatosis Type 1
1. Plexiform Neurofibroma
2. Optic Nerve Glioma
3. Uveal Melanoma
4. Malignant Peripheral Nerve Sheath Tumors
5. Chronic Myeloid Leukemia
6. Myelofibrosis
7. Kaposi's Sarcoma
8. Malignant Neoplasm of Breast
9. Malignant Neoplasms of Digestive Organs
10. Malignant Neoplasms of Female Genital Organs
11. Malignant Neoplasms of Male Genital Organs
12. Malignant Neoplasms of Thyroid and other Endocrine Gland
13. Triple-Negative Breast Cancer
14. Squamous Cell Lung Cancer
15. Non-squamous Cell Lung Cancer with KRAS Mutations
16. Non-squamous Cell Lung Cancer with Wild-type KRAS

Side Effects

Sources

1. ChemSpider. "Selumetinib." http://www.chemspider.com/Chemical-Structure.8303141.html
2. CinicalTrials.gov "Selumetinib Trials USA"
   https://clinicaltrials.gov/ct2/results?term=Selumetinib&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&recrs=g&recrs=h&recrs=e&recrs=i&recrs=m&age_v=&gndr=&type=&rslt=
3. Dombi, Eva, et al. "Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas." New England Journal of Medicine 375.26 (2016): 2550-2560.
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508592/
4. Balagula, Yevgeniy, et al. "Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)." Investigational new drugs 29.5 (2011): 1114-1121.
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691597/ | DOI: https://doi.org/10.1007/s10637-010-9567-3
5. Casaluce, Francesca, et al. "Selumetinib for the treatment of non-small cell lung cancer." Expert opinion on investigational drugs 26.8 (2017): 973-984.
   https://www.tandfonline.com/doi/abs/10.1080/13543784.2017.1351543 | DOI: https://doi.org/10.1080/13543784.2017.1351543
6. Wallace, Eli M., et al. "Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof." U.S. Patent No. 8,193,231. (5 Jun. 2012).
   https://patents.google.com/patent/US8193231B2/en
7. Wallace, Eli M., et al. "Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors." U.S. Patent No. 8,193,229. 5 Jun. 2012.
   https://patents.google.com/patent/US8193229B2/en